Company intelligence / Profile preview

Durin Technologies

Ownership: Private
Development stage: Commercial

Overview

Duritect™ tests, including Duritect-AD™ for Alzheimer's and Duritect-PD™ for Parkinson's, have demonstrated high accuracy, sensitivity, and specificity as blood-based biomarker diagnostics; early results presented at AAIC 2024.

Therapeutic areas: Neurology
Modalities: Diagnostic testBlood-based biomarkerIn vitro diagnostic
Industry: Protein Biomarker Diagnostics

Drug pipeline

2 assets

Duritect-AD

Commercial

Indications: Alzheimer's disease

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Durin Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Durin Technologies.

Explore the full profile